Abstract Library

#4667 Clinical outcomes in patients with typical (TC) and atypical bronchial carcinoids (AC): A 15-year retrospective study from an ENETS Center of Excellence

Introduction: Bronchial neuroendocrine neoplasms (NENs) can be subdivided into TCs, ACs and neuroendocrine carcinomas (NECs). Although a few studies have explored treatment approaches and oncological outcomes, most focus on surgical cohorts, small sample sizes, or mixed groups including TC, AC, and NECs. Real-life cohort data are lacking.

Conference:

Presenting Author: Clement D

Authors: Correia J, Sarker D, Dolly S, Frydman A, Srirajaskanthan R,

Keywords: bronchial carcinoid, treatment pattern, recurrence-free survival, overall survival,

#4658 The nutritional status worsens over 5 years in patients with gastroenteropancreatic neuroendocrine tumours on treatment with somatostatin analogues

Introduction: Malnutrition is common in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) treated with monthly somatostatin analogues (SSAs). Ideally all malnourished patients are offered nutritional support. However, clinical guidelines and data on the development and progression of malnutrition is lacking.

Conference:

Presenting Author: Clement D

Authors: Soran V, Srirajaskanthan R, Cananea E, Martin W, Minott S,

Keywords: gastroenteropancreatic neuroendocrine tumour, malnutrition, somatostatin analogue,

#4641 Case series: Tuberous sclerosis associated pancreatic neuroendocrine tumours at a tertiary centre

Introduction: Tuberous sclerosis (TSC) is an autosomal dominant condition which can increase the risk of pancreatic neuroendocrine tumours (PanNETs) (1). Patients with TSC undergo screening for renal tumours which may include pancreatic imaging (2). There are currently no screening guidelines for PanNETs in patients with TSC.

Conference:

Presenting Author: Frydman A

Authors: Frydman A, Clement D, Srirajaskanthan R,

Keywords: Pancreas neuroendocrine tumour, Tuberous sclerosis,

#4632 MEN1 associated pancreatic neuroendocrine tumours: Re-evaluating the 2cm cut-off for surgical resection

Introduction: Pancreatic neuroendocrine tumours (PanNETs) are the leading cause of death in patients (pts) with MEN1. Screening is recommended to diagnose early and prevent metastases. The optimal cut-off of when to intervene in a PanNET is still an area of debate.

Conference:

Presenting Author: Frydman A

Authors: Frydman A, Clement D, Srirajaskanthan R,

Keywords: MEN1, Pan NET,

#4611 Management strategies and outcomes for type 1 gastric neuroendocrine tumours measuring > 1cm in diameter

Introduction: Although type 1 gastric neuroendocrine tumours (T1-gNETs) are usually considered indolent diseases, the management and the outcome of tumours >1cm remain not well established.

Conference:

Presenting Author:

Authors: Dell' Unto E, Srirajaskanthan R, Saini A, Salin G, de Mestier L,

Keywords: gastric neuroendocrine tumour, gastric carcinoid, endoscopic treatment,